Edwards Lifesciences (NYSE:EW) Announces Earnings Results

Edwards Lifesciences (NYSE:EW) issued its quarterly earnings results on Wednesday. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01, Briefing.com reports. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.66 earnings per share. Edwards Lifesciences updated its Q3 guidance to $0.67-0.71 EPS and its Q3 2024 guidance to 0.670-0.710 EPS.

Edwards Lifesciences Stock Up 4.5 %

Shares of NYSE:EW traded up $2.67 on Friday, reaching $62.37. The company had a trading volume of 14,111,391 shares, compared to its average volume of 5,310,790. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12. The firm’s 50 day simple moving average is $87.98 and its 200-day simple moving average is $86.84. The firm has a market capitalization of $37.58 billion, a PE ratio of 26.88, a PEG ratio of 2.22 and a beta of 1.11. The company has a current ratio of 3.71, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Insider Activity

In other news, CFO Scott B. Ullem sold 7,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total value of $622,050.00. Following the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at approximately $1,636,549.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Scott B. Ullem sold 7,250 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total value of $622,050.00. Following the completion of the sale, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,636,549.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 5,625 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $90.45, for a total value of $508,781.25. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,764,242.45. The disclosure for this sale can be found here. In the last three months, insiders have sold 81,099 shares of company stock worth $7,003,553. 1.29% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

EW has been the subject of several research analyst reports. Baird R W cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Piper Sandler cut their target price on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research report on Thursday. Bank of America cut Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their target price for the stock from $105.00 to $75.00 in a research report on Thursday. Barclays cut their target price on Edwards Lifesciences from $101.00 to $90.00 and set an “overweight” rating for the company in a research report on Friday. Finally, The Goldman Sachs Group dropped their price target on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research note on Friday. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $82.10.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.